GlassScriptPhysician profile
Luigi U Baretto
NPI 1619361011
$1,493.07
in general payments reported to CMS, 2019-2025
21 companies · $472 in 2025
The $472 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $219 · 2020: $184 · 2021: $130 · 2022: $230 · 2023: $88.50 · 2024: $170 · 2025: $472.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $730.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $730.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $458.26 | 2019-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $163.79 | 2019-2025 | Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $126.73 | 2022-2025 | Airsupra, Breztri, Farxiga |
| Pfizer INC. | $100.74 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $97.22 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $92.60 | 2021-2025 | Jardiance |
| Abbvie INC. | $92.51 | 2020-2025 | |
| Astellas Pharma US INC | $51.08 | 2023-2025 | Veozah |
| Exact Sciences Corporation | $48.69 | 2024-2025 | Cologuard Collection Kit |
| Hologic Sales and Service, LLC | $38.61 | 2025 | Aptima |
| Abbott Laboratories | $33.88 | 2022-2025 | Freestyle Libre 3 |
| Teva Pharmaceuticals USA, INC. | $28.95 | 2021 | |
| Ibsa Pharma INC. | $28.57 | 2022-2024 | Licart, Tirosint |
| Merck Sharp & Dohme LLC | $26.96 | 2019 | |
| Axsome Therapeutics, INC. | $19.00 | 2025 | Auvelity |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aytu Biopharma, INC. | $16.23 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $15.88 | 2025 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $14.69 | 2025 | |
| Daiichi Sankyo INC. | $13.98 | 2023 | Injectafer |
| E.R. Squibb & Sons, L.L.C. | $12.78 | 2019 | |
| Sanofi Pasteur INC. | $11.92 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luigi Baretto listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.